Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: review decision - January 2015
Review of NICE Technology Appraisal Guidance No. 269; Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma
The Institute was proposing that the existing guidance should be incorporated into an ongoing clinical guideline on the assessment and management of malignant melanoma. This would mean that the current Patient Access Scheme for vemurafenib would remain in place
During consultation, the majority of comments received by the Institute agreed with the proposal put forward. After consideration of all of the comments (attached as appendix A), the Institute’s Guidance Executive has decided to proceed with the proposal.
Consequently, TA269 will be incorporated into the ongoing clinical guideline on the assessment and management of malignant melanoma, anticipated to be published in July 2015. The existing recommendations will move to the technology appraisal static list and the current Patient Access Scheme for vemurafenib will remain in place.
This page was last updated: 20 January 2015